Journal
INTERNATIONAL JOURNAL OF HYPERTHERMIA
Volume 34, Issue 8, Pages 1316-1328Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02656736.2018.1430867
Keywords
Magnetic hyperthermia therapy; magnetic nanoparticles; glioblastoma; convection enhanced delivery; alternating magnetic field
Funding
- NATIONAL CANCER INSTITUTE [R01CA194574] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA194574] Funding Source: Medline
Ask authors/readers for more resources
Hyperthermia therapy (HT) is the exposure of a region of the body to elevated temperatures to achieve a therapeutic effect. HT anticancer properties and its potential as a cancer treatment have been studied for decades. Techniques used to achieve a localised hyperthermic effect include radiofrequency, ultrasound, microwave, laser and magnetic nanoparticles (MNPs). The use of MNPs for therapeutic hyperthermia generation is known as magnetic hyperthermia therapy (MHT) and was first attempted as a cancer therapy in 1957. However, despite more recent advancements, MHT has still not become part of the standard of care for cancer treatment. Certain challenges, such as accurate thermometry within the tumour mass and precise tumour heating, preclude its widespread application as a treatment modality for cancer. MHT is especially attractive for the treatment of glioblastoma (GBM), the most common and aggressive primary brain cancer in adults, which has no cure. In this review, the application of MHT as a therapeutic modality for GBM will be discussed. Its therapeutic efficacy, technical details, and major experimental and clinical findings will be reviewed and analysed. Finally, current limitations, areas of improvement, and future directions will be discussed in depth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available